Overview

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a 3 part, phase 1 crossover study in healthy subjects to evaluate the pharmacokinetic profile of KVD824 following single and multiple doses of novel KVD824 modified-release formulations compared with a reference KVD824 immediate release formulation.
Phase:
Phase 1
Details
Lead Sponsor:
KalVista Pharmaceuticals, Ltd.